tropisetron / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 0 Diseases   44 Trials   44 Trials   130 News 


«123»
  • ||||||||||  pentylenetetrazole (BTD-001) / Balance Therap
    Preclinical, Journal:  Anticonvulsant Effect of Minocycline on Pentylenetetrazole-Induced Seizure in Mice: Involvement of 5-HT3 Receptor. (Pubmed Central) -  Jun 11, 2022   
    In addition, the 5-HT antagonist, tropisetron, at doses that had no effect on seizure threshold, augmented the anticonvulsant effect of minocycline (40 mg/kg), while mCPBG (0.2 mg/kg) blunted the anticonvulsant effect of minocycline (80 mg/kg). In conclusion, our findings revealed that the anticonvulsant effect of minocycline is mediated, at least in part, by inhibition of 5-HT receptor.
  • ||||||||||  tropisetron / Generic mfg.
    Journal:  Deep Learning Applications for the accurate identification of low-transcriptional activity drugs and their mechanism of actions. (Pubmed Central) -  May 29, 2022   
    Lastly, in biological validation of the MOA prediction for a TAS-low drug Tropisetron, we found an unreported mechanism that Tropisetron can bind to the glucocorticoid receptor. This study indicated that GPAR can serve as an effective approach for the accurate identification of low-transcriptional activity drugs and their MOAs, thus providing a good tool for drug repurposing with both TAS-low and TAS-high signatures.
  • ||||||||||  tropisetron / Generic mfg.
    Journal:  To Explore the Effects of Acupuncture and Medical Treatment at Different Times on the Gastrointestinal Reaction and White Blood Cell Count of Patients with Lung Cancer Chemotherapy. (Pubmed Central) -  Apr 19, 2022   
    The effective rates of the control group, study group 1, and study group 2 were 42.11%, 82.05%, and 62.86%, respectively; compared with that of the control group, the treatment efficiency of study groups 1 and 2 was higher and the difference between the three groups was statistically significant (P < 0.05). Tropisetron hydrochloride is an effective treatment for patients with lung cancer before chemotherapy, which can effectively improve the side effects of nausea and vomiting caused by chemotherapy, reduce the white blood cell count, and improve the quality of life of patients; it plays an important role in the improvement of prognosis.
  • ||||||||||  Enrollment open:  HELEN-009: Anti-emetic Prophylaxis With or Without Dexamethasone (clinicaltrials.gov) -  Apr 18, 2022   
    P3,  N=403, Recruiting, 
    Tropisetron hydrochloride is an effective treatment for patients with lung cancer before chemotherapy, which can effectively improve the side effects of nausea and vomiting caused by chemotherapy, reduce the white blood cell count, and improve the quality of life of patients; it plays an important role in the improvement of prognosis. Active, not recruiting --> Recruiting
  • ||||||||||  ondansetron / Generic mfg.
    Review, Journal:  Selective 5HT3 antagonists and sensory processing: a systematic review. (Pubmed Central) -  Mar 3, 2022   
    Despite these limitations, we found strong evidence that selective 5HT3 antagonists (with or without direct α7-nicotinic partial agonist effects) improved sensory gating. Future studies should investigate how this relates to potential improvement in neurocognitive symptoms in antipsychotic naive patients with prodromal or milder symptoms, in order to understand the clinical implications.
  • ||||||||||  ondansetron / Generic mfg.
    Journal:  Synthesis and Development of Indole Based 5-HT3 Receptor Antagonists as Anti-Emetic Drugs in Oncology: An Update. (Pubmed Central) -  Jan 7, 2022   
    This revision is focused on compounds bearing an indole core that present a 5-HT3 receptor antagonist activity that has been successfully used as anti-emetic drugs, reducing chemotherapy adverse secondary effects during cancer treatment. Their synthesis, biological activities, and some outstanding characteristics are discussed, affording a general outlook towards the development of more efficient anti-emetic drugs.
  • ||||||||||  RO5263397 / Roche, SRI International, Miostat (carbachol) / Novartis
    Preclinical, Journal:  Differential effects of β-methylphenylethylamine and octopamine on contractile parameters of the rat gastrointestinal tract. (Pubmed Central) -  Jan 7, 2022   
    Contrarily, EPPTB did not reduce the relaxant effects of RO5263397 (TA agonist) or zacopride (5-HT agonist)...Intestinal preparations previously contracted with carbachol relaxed after the addition of octopamine and decreased the magnitude of their spontaneous rhythmic contractions in a tropisetron-dependent manner...Octopamine inhibited the rat gut contractility through the likely involvement of 5-HT and TA receptors. Overall, octopamine effectively inhibited rat gastrointestinal transit.
  • ||||||||||  Varubi (rolapitant oral) / TerSera Therap, GSK
    Retrospective data, Review, Journal:  Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis. (Pubmed Central) -  Dec 16, 2021   
    For people receiving HEC, synthesised evidence does not suggest one superior treatment for prevention and control of chemotherapy-induced nausea and vomiting.  For people receiving MEC, synthesised evidence does not suggest superiority for treatments including both NK₁ and 5-HT₃ inhibitors when compared to treatments including 5-HT₃ inhibitors only. Rather, the results of our NMA suggest that the choice of 5-HT₃ inhibitor may have an impact on treatment efficacy in preventing CINV.  When interpreting the results of this systematic review, it is important for the reader to understand that NMAs are no substitute for direct head-to-head comparisons, and that results of our NMA do not necessarily rule out differences that could be clinically relevant for some individuals.
  • ||||||||||  metoclopramide / Generic mfg.
    Journal:  MASCC antiemetics in advanced cancer updated guideline. (Pubmed Central) -  Oct 30, 2021   
    The present data also shed light on a new aspect of tropisetron immuno-modulatory action that engaged TLR2, TLR4, and JAK2/STAT3 signalling cascades. First-line antiemetics for nausea and vomiting in advanced cancer are metoclopramide and haloperidol, and second-line medications are methotrimeprazine and olanzapine.
  • ||||||||||  glibenclamide / Generic mfg., tropisetron / Generic mfg.
    Preclinical, Journal:  Ameliorative effects of tropisetron on liver injury in streptozotocin-induced diabetic rats. (Pubmed Central) -  Sep 30, 2021   
    These effects were equipotent with glibenclamide, suggesting that tropisetron treatment is associated with a hepatoprotective effect against diabetic injury. Therefore, the results of this study manifested the significance of using tropisetron as a promising remedial agent to improve diabetic complications.
  • ||||||||||  tropisetron / Generic mfg.
    Preclinical, Journal:  Tropisetron enhances recognition memory in ovariectomized female rats. (Pubmed Central) -  Sep 9, 2021   
    Hormonal-priming with estrogen, progesterone, or estrogen + progesterone did not further accentuate the effects of tropisetron. These results suggest that although tropisetron, estrogen, and progesterone all act as antagonists at the 5-HT3 receptors and blocking 5-HT3 receptors enhances cognition, there appears to be no interaction between tropisetron and these hormones on object recognition.
  • ||||||||||  oxaliplatin / Generic mfg., tropisetron / Generic mfg.
    Clinical, Review:  Intra-arterial chemoembolization with chemotherapy for unresectable locally advanced rectal cancer: a case report and literature review. (Pubmed Central) -  Sep 8, 2021   
    During the first time of the mFOLFOX6 regimen, the patient had severe side effects of vomiting, despite tropisetron being routinely given...After intra-arterial chemoembolization with oxaliplatin and 3 months of chemotherapy with CAPEOX regimen, CT and MRI were performed again to re-evaluate the local condition...We concluded that the tumor was converted into a resectable one, and the patient met the conditions for the operation. The fact indicates that it is effective in creating good operative conditions for LARC by adding intra-arterial chemotherapy to the standard treatment.
  • ||||||||||  Akynzeo oral (netupitant/palonesteron FDC) / Helsinn, Roche, Otsuka, Mundipharma, Immedica
    New P4 trial:  Oral Akynzeo (clinicaltrials.gov) -  Mar 25, 2021   
    P4,  N=530, Recruiting, 
  • ||||||||||  Alfenta (alfentanil) / Abbott, Sufenta (sufentanil) / Akorn, Emestop (ramosetron hydrochloride) / Samyang Group
    Trial completion, Enrollment change:  Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis (clinicaltrials.gov) -  Jan 26, 2018   
    P=N/A,  N=48246, Completed, 
    N=48246 --> 27034 Recruiting --> Completed | N=32000 --> 48246
  • ||||||||||  Alfenta (alfentanil) / Abbott, Sufenta (sufentanil) / Akorn, Emestop (ramosetron hydrochloride) / Samyang Group
    Trial primary completion date:  Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis (clinicaltrials.gov) -  Nov 6, 2017   
    P=N/A,  N=32000, Recruiting, 
    Recruiting --> Completed | N=32000 --> 48246 Trial primary completion date: Jul 2017 --> Nov 2017
  • ||||||||||  Alfenta (alfentanil) / Abbott, Sufenta (sufentanil) / Akorn, Emestop (ramosetron hydrochloride) / Samyang Group
    Trial primary completion date:  Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis (clinicaltrials.gov) -  Mar 27, 2017   
    P=N/A,  N=32000, Recruiting, 
    Trial primary completion date: Jul 2017 --> Nov 2017 Trial primary completion date: Feb 2017 --> Jul 2017
  • ||||||||||  Alfenta (alfentanil) / Abbott, Sufenta (sufentanil) / Akorn, Emestop (ramosetron hydrochloride) / Samyang Group
    Enrollment open:  Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis (clinicaltrials.gov) -  Jul 20, 2016   
    P=N/A,  N=32000, Recruiting, 
    Not yet recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
  • ||||||||||  Alfenta (alfentanil) / Abbott, Sufenta (sufentanil) / Akorn, Emestop (ramosetron hydrochloride) / Samyang Group
    Trial initiation date, Trial primary completion date:  Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis (clinicaltrials.gov) -  Mar 30, 2016   
    P=N/A,  N=32000, Not yet recruiting, 
    Not yet recruiting --> Recruiting Initiation date: Dec 2015 --> May 2016 | Trial primary completion date: Aug 2016 --> Dec 2016